Stock Detail
NOVOGEN LIMITED - AMERICAN DEPOSITARY SHARES EACH REPRESENTING FIVE ORDINARY SHARES
Drug Manufacturers Major
NVGN @ Yahoo Finance | NVGN Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $0.50 | $0.53 | $0.02 | 3.69% | 0.00 | $0.48 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $0.49 | $0.49 | 47,463 | 10.21M | 41,699 | -0.96 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 0.55 | 0.53 | 0.51 | 0.49 | 0.47 |
Stock Profile
Novogen Limited, a pharmaceutical company, engages in the discovery, development, manufacture, and marketing of products based on the isoflavoniod technology. Its product development program comprises a novel range of pharmaceuticals based on phenolic compounds in humans, and dietary supplements based on plant compounds known as isoflavones. The company's products include Promensil, which provides natural relief from the symptoms of menopause, such as hot flushes and night sweats; Trinovin, which maintains normal prostate and urinary function, health and quality of life in men; and Rimostil that maintains bone and cholesterol health, and also to promote health and well-being in women after menopause. In addition, Novogen develops phenoxodiol, which is in phase II clinical trials for the treatment of prostate cancer, ovarian cancer, renal cancer, and squamous cell carcinomas of the cervix, vagina, and vulva. It is also developing NV-04, a cardiovascular drug candidate; and NV-07, an anti-inflammatory drug candidate. The company sells its products through its distributors and other third parties in Australia, New Zealand, the United States, Canada, and certain European countries. Novogen was founded by Graham E. Kelly in 1994. It was formerly known as Norvet Limited. The company is headquartered in North Ryde, Australia.